Ignite Creation Date:
2024-05-05 @ 4:39 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00281008
Status:
COMPLETED
Last Update Posted:
2016-08-03
First Post:
2006-01-20
Brief Title:
Study of ISIS 301012 Mipomersen in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy
Sponsor:
Kastle Therapeutics LLC
Organization:
Kastle Therapeutics LLC
Study Overview
Official Title:
A Phase 2 Double-Blind Placebo-Controlled Dose Escalation Study to Assess the Safety Efficacy and Pharmacokinetics of ISIS 301012 as Add-on Therapy in Heterozygous Familial Hypercholesterolemia Subjects
Status:
COMPLETED
Status Verified Date:
2016-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 mipomersen as add-on therapy in subjects with Heterozygous Familial Hypercholesterolemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005-004797-24 | EUDRACT_NUMBER | None | None |